肿瘤浸润性 T 淋巴细胞治疗后外源人类疱疹病毒 6 再感染。
Exogenous human herpesvirus 6 reinfection after tumor-infiltrating T-lymphocyte therapy.
机构信息
Laboratory of Virology, University Hospital of Grenoble, Grenoble, France; Irkutsk State Medical University, Ministry of Health of Russia, Irkutsk, Russia.
Dermatology Unit, Univ. Grenoble Alpes, IAB, University Hospital of Grenoble, Grenoble, France.
出版信息
Cytotherapy. 2018 Apr;20(4):521-523. doi: 10.1016/j.jcyt.2017.12.006. Epub 2018 Feb 9.
Exogenous human herpes virus 6 (HHV-6) reinfection has never been reported in patients receiving tumor-infiltrating T lymphocytes therapy. We report an unusual case of HHV-6 infection following infusion of HHV-6 infected autologous T lymphocytes. HHV-6 infection could interfere with the tumor antigen immune recognition and the efficacy of immunotherapy.
接受过肿瘤浸润性 T 淋巴细胞治疗的患者从未报告过外源性人类疱疹病毒 6（HHV-6）再感染。我们报告了一例在输注 HHV-6 感染的自体 T 淋巴细胞后发生 HHV-6 感染的不寻常病例。HHV-6 感染可能会干扰肿瘤抗原的免疫识别和免疫疗法的疗效。
Zotero 插件